What is Granulation Technology?
Granulation Technology, Inc. operates as a sophisticated nexus for chemical and pharmaceutical manufacturing, providing end-to-end product development solutions. By maintaining rigorous adherence to Good Laboratory Practice (GLP) and Good Manufacturing Practice (GMP) standards, the company serves a diverse clientele ranging from agile small-cap enterprises to established Fortune 500 organizations. Their core competency lies in formulation and analytical development, supported by a portfolio of FDA-approved medications including Prednisone, Carisoprodol, and Methocarbamol. This technical proficiency allows the firm to bridge the gap between early-stage research and commercial-scale distribution, positioning it as a critical partner in the global pharmaceutical supply chain.
How much funding has Granulation Technology raised?
Granulation Technology has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in Granulation Technology
PPP
Public-Private Partnership
What's next for Granulation Technology?
With this late-stage financing secured, Granulation Technology is well-positioned to optimize its manufacturing throughput and expand its analytical service offerings. The strategic deployment of this capital will likely focus on enhancing facility capabilities to meet increasing regulatory demands and market volume requirements. By leveraging its existing expertise in drug formulation, the company is poised to capture additional market share, potentially diversifying its therapeutic offerings and strengthening its footprint in the life sciences sector. Future growth will likely be defined by the firm's ability to maintain its high-quality manufacturing standards while scaling operations to accommodate a broader range of complex pharmaceutical development projects.
See full Granulation Technology company page
